Skip to content

Antonios Aliprantis

Vice President, Program Leadership, Pioneering Medicines

Antonios (Tony) Aliprantis is Flagship Pioneering's Vice President, Program Leadership of Pioneering Medicines. He is responsible for leading cross functional teams to create integrated development strategies for programs between lead optimization and human proof of concept. Tony also contributes to new product concept explorations at Pioneering Medicines.

Tony is a physician scientist and clinically trained rheumatologist. Prior to joining Pioneering Medicines, he was the Vaccines Therapeutic Area Lead in the Translational Pharmacology group at Merck where he oversaw a portfolio of early vaccine programs. In his 6 years at Merck, Tony led multiple early development programs, including an mRNA vaccine and a monoclonal antibody, each for Respiratory Syncytial Virus prevention, and provided clinical pharmacology support to the recent successful filing of vericiguat, a small molecule for heart failure patients. Tony also led human discovery medicine studies, including one of the largest investigations of the role of the microbiome in vaccine responses.

Prior to Merck, Tony was a faculty member for 8 years at Brigham and Women’s Hospital and Harvard Medical School and ran an NIH-funded laboratory investigating bone biology, inflammation, arthritis, and fibrosis. Tony received his MD, PhD from NYU School of Medicine where he studied the role of Toll-like receptors in innate immunity.